@article{dd1c71a5d23f42a89ca2145e7cebc395,
title = "Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report",
abstract = "The aim of this study was to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in four patients with locally advanced breast cancer by simultaneous PET/MRI. Four patients with locally advanced breast cancer underwent simultaneous PET/MRI of the breast using a 3 T Biograph mMR before and after neo-adjuvant chemotherapy (two patients were treated with hormone-therapy and two patients were treated with cytotoxic chemotherapy). Morpho-structural tumoral features and tumor size were assessed; area value, metabolic (SUV and MTV) and functional (ADC, Ktrans, Ve, kep and iAUC) data were obtained by positioning regions of interest. A comparison of all parameters between the pre- and post-treatment PET/MRI examinations and between the two different therapeutic schedules was assessed. In patients treated with cytotoxic chemotherapy and classified as PR, there was a significant reduction of post-treatment morphological, metabolic and functional parameters. In a patient treated with hormone therapy, classified as SD, there was an increase of all post-treatment perfusion parameters, a substantially stable ADC value and a poor reduction of lesion size and of maximum SUV (SUVmax) values; the last patient, treated with hormone therapy and classified as PR, showed a significant reduction of lesion size and SUVmax values with a reduction of perfusion parameters and substantially stable ADC values. Multiparametric evaluation with simultaneous PET/MRI could be a useful tool to assess the response to cytotoxic and hormone neo-adjuvant chemotherapy in patients with breast cancer. Future studies in a larger cohort of patients are warranted to confirm the results of this preliminary study. {\textcopyright} 2016, Springer Science+Business Media New York.",
keywords = "Breast cancer, Neo-adjuvant chemotherapy, Simultaneous PET/MRI, cytotoxic agent, fluorodeoxyglucose f 18, hormone, antineoplastic agent, antineoplastic hormone agonists and antagonists, adult, aged, apparent diffusion coefficient, Article, breast cancer, breast carcinoma, cancer adjuvant therapy, cancer chemotherapy, cancer growth, cancer hormone therapy, cancer morphology, cancer patient, cancer size, case report, cytotoxicity, female, functional assessment, human, initial area under the concentration curve, metabolic tumor volume, middle aged, nuclear magnetic resonance imaging, oncological parameters, PET-MRI scanner, positron emission tomography, priority journal, standard uptake volume, treatment response, adjuvant chemotherapy, Breast Neoplasms, diagnostic imaging, multimodal imaging, neoadjuvant therapy, procedures, Adult, Aged, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Chemotherapy, Adjuvant, Female, Humans, Magnetic Resonance Imaging, Middle Aged, Multimodal Imaging, Neoadjuvant Therapy, Positron-Emission Tomography",
author = "V. Romeo and M. D{\textquoteright}Aiuto and G. Frasci and M. Imbriaco and E. Nicolai",
note = "Export Date: 5 March 2018 CODEN: MONCE Correspondence Address: Romeo, V.; Department of Advanced Biomedical Sciences, University Federico II of Naples, Via S. Pansini, 5, Italy; email: valeria.romeo@unina.it Chemicals/CAS: fluorodeoxyglucose f 18, 63503-12-8; Antineoplastic Agents; Antineoplastic Agents, Hormonal Tradenames: 3 T Biograph mMR, Siemens Healthcare, Germany Manufacturers: Siemens Healthcare, Germany References: Rosenkrantz, A.B., Friedman, K., Chandarana, H., Current status of hybrid PET/MRI in oncologic imaging (2016) AJR Am J Roentgenol, 206 (1), pp. 162-172. , PID: 26491894; Ho, A.M., Kalantari, B.N., PET/MRI: a new frontier in breast cancer imaging (2016) Breast J, 22 (3), pp. 261-263. , PID: 27191359; Tabouret-Viaud, C., Botsikas, D., Delattre, B.M., PET/MR in breast cancer (2015) Semin Nucl Med, 45 (4), pp. 304-321. , PID: 26050658; Margolis, N.E., Moy, L., Sigmund, E.E., Assessment of aggressiveness of breast cancer using simultaneous 18F-FDG-PET and DCE-MRI: preliminary observations (2016) Clin Nucl Med, 41 (8), pp. e355-e361. , PID: 27187730; Eiber, M., Martinez-M{\"o}ller, A., Souvatzoglou, M., Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions (2011) Eur J Nucl Med Mol Imaging, 38 (9), pp. 1691-1701. , PID: 21688050; Eisenhauer, E.A., Therasse, P., Bogaerts, J., New response evaluation criteria in solid tumours; Revised RECIST guideline (version 1.1) (2009) Eur J Cancer, 45 (2), pp. 228-247. , COI: 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D, PID: 19097774; Jh, O., Lodge, M.A., Wahl, R.L., Practical PERCIST: a simplified Guide to PET response criteria in solid tumors 1.0 (2016) Radiology, 280 (2), pp. 576-584. , PID: 26909647; Tofts, P.S., Kermode, A.G., Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts (1991) Magn Reson Med, 17 (2), pp. 357-367. , COI: 1:STN:280:DyaK3M3oslGiug%3D%3D, PID: 2062210; Tateishi, Y., Miyake, M., Nagaoka, T., Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging—prospective assessment (2012) Radiology, 263 (1), pp. 53-63. , PID: 22438441; Weber, W.A., Schwaiger, M., Avril, N., Quantitative assessment of tumor metabolism using FDG-PET imaging (2000) Nucl Med Biol, 27 (7), pp. 683-687. , COI: 1:CAS:528:DC%2BD3cXot1ygsro%3D, PID: 11091112; Xu, Q.G., Xian, J.F., Role of quantitative magnetic resonance imaging parameters in the evalution of treatment response in malignant tumors (2015) Chin Med J, 128 (8), pp. 1128-1133. , PID: 25881611; Yankeelov, T.E., Lepage, M., Chakravarthy, A., Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer (2007) Magn Reson Imaging, 25 (1), pp. 1-13. , PID: 17222711",
year = "2017",
month = feb,
doi = "10.1007/s12032-016-0876-z",
language = "English",
volume = "34",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "2",
}